ATE533486T1 - Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung - Google Patents

Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung

Info

Publication number
ATE533486T1
ATE533486T1 AT06791093T AT06791093T ATE533486T1 AT E533486 T1 ATE533486 T1 AT E533486T1 AT 06791093 T AT06791093 T AT 06791093T AT 06791093 T AT06791093 T AT 06791093T AT E533486 T1 ATE533486 T1 AT E533486T1
Authority
AT
Austria
Prior art keywords
pyridone derivatives
preventing
lung injury
radiotherapy
related lung
Prior art date
Application number
AT06791093T
Other languages
English (en)
Inventor
Tieling Zhou
Ying Luo
Jun Wu
Original Assignee
Shanghai Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Genomics Inc filed Critical Shanghai Genomics Inc
Application granted granted Critical
Publication of ATE533486T1 publication Critical patent/ATE533486T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT06791093T 2006-06-15 2006-09-25 Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung ATE533486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80491406P 2006-06-15 2006-06-15
PCT/CN2006/002504 WO2007147297A1 (en) 2006-06-15 2006-09-25 The use of derviate of pyridone for preventing and treating radioactive injury of lungs

Publications (1)

Publication Number Publication Date
ATE533486T1 true ATE533486T1 (de) 2011-12-15

Family

ID=38833053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06791093T ATE533486T1 (de) 2006-06-15 2006-09-25 Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung

Country Status (7)

Country Link
US (2) US8765726B2 (de)
EP (1) EP2036555B1 (de)
JP (1) JP5213852B2 (de)
CN (1) CN101484167B (de)
AT (1) ATE533486T1 (de)
CA (1) CA2656017C (de)
WO (1) WO2007147297A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767700B2 (en) 2006-12-18 2010-08-03 Intermune, Inc. Method of providing pirfenidone therapy to a patient
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20100190731A1 (en) * 2009-01-26 2010-07-29 Jeff Olgin Methods for treating acute myocardial infarctions and associated disorders
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2016127013A1 (en) * 2015-02-05 2016-08-11 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
WO2020232101A1 (en) * 2019-05-13 2020-11-19 Bio Med Sciences, Inc. Active ingredient woundcare and scar management products, process of manufacture and useful articles thereof
CN115429802A (zh) * 2021-06-04 2022-12-06 北京康蒂尼药业股份有限公司 包含羟尼酮与右美沙芬的药物组合物及其治疗肺纤维化的应用
CN113274389B (zh) * 2021-07-09 2022-11-08 中南大学 氟非尼酮在制备治疗急性肺损伤药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
AU5427080A (en) 1979-01-08 1980-07-17 Margolin, B. Pirfenidone in the treatment of pulmonary interstitial fibrosis
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
WO1994026249A1 (en) 1993-05-07 1994-11-24 Margolin Solomon B Compositions and methods for reparation and prevention of fibrotic lesions
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6114353A (en) * 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
CA2388840C (en) * 2000-01-24 2011-09-13 Solomon B. Margolin Treatment of lymphomas, leukemias, breast carcinomas, astrocytomas, melanomas, leiomyomas, and related tumors
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
US20060110358A1 (en) * 2002-08-28 2006-05-25 Hsu Henry H Combination therapy for treatment of fibrotic disorders
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2545813C (en) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途

Also Published As

Publication number Publication date
EP2036555A4 (de) 2009-11-11
EP2036555A1 (de) 2009-03-18
CA2656017C (en) 2014-02-04
EP2036555B1 (de) 2011-11-16
WO2007147297A1 (en) 2007-12-27
CN101484167A (zh) 2009-07-15
JP2009539887A (ja) 2009-11-19
US20080161361A1 (en) 2008-07-03
CA2656017A1 (en) 2007-12-27
US8765726B2 (en) 2014-07-01
US20140249347A1 (en) 2014-09-04
CN101484167B (zh) 2012-07-04
JP5213852B2 (ja) 2013-06-19

Similar Documents

Publication Publication Date Title
ATE533486T1 (de) Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
BRPI0506736A (pt) composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central
EA201590353A1 (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
ATE521608T1 (de) Glucokinaseaktivatoren
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
MY174018A (en) Heterocyclic derivates
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
ATE551996T1 (de) Behandlung oder prävention von diabetes mit cannabidiol
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
WO2008090287A3 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida
DE602005008241D1 (de) Zusammensetzung mit einem survivin-antisense-oligonucleotid und gemcitabin zur behandlung von krebs
DE602005009162D1 (de) Alpha-aminoamidderivate zur behandlung des restless-leg-syndroms
ATE424208T1 (de) Proteinkinaseinhibitoren
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs